Information Provided By:
Fly News Breaks for January 15, 2019
NBIX
Jan 15, 2019 | 07:47 EDT
Ingrezza sales in Q4 of $130M demonstrate the commercial strength of the drug and should assuage investors' concerns of the future growth of Neurocrine Biosciences in light of the topline miss in Tourette syndrome, H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst continues to believe Neurocrine's 2019 value proposition Is attractive. He reiterates a Buy rating on the shares with a $102 price target.
News For NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.